News
Featured
- Publication
- 22-06-2016
Efficacy and safety of an anti-CD20 monoclonal antibody (Reditux) for the treatment of patients with moderate to severe rheumatoid arthritis following the failure of conventional synthetic disease-modifying anti-rheumatic drugs
- News
- 28-11-2024
Dr Reddy's launches novel cancer therapy Toripalimab in India
- Article
- 30-09-2023
Temperature Upshifts in Mammalian Cell Culture: A Suitable Strategy for Biosimilar Monoclonal Antibodies?
- Publication
- 12-02-2020
Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus ReferenceRituximab in Biologics‑Naïve Patients with Moderate‑to‑SevereRheumatoid Arthritis: A Double‑Blind, Randomized, Three‑Arm Study
Explore Resources
Ankit Kr. Dubey
Product Dev.
Gargi Mazumdar
CAR-T
Nithin
Quality
Jasmit Singh
Business Dev.
Gangadhara Rao
Manufacturing
Bricks of Biologics, appreciates the contribution and celebrates our people who are the building blocks of Dr. Reddy's Biologics.
Bricks of biologics in general refers to bio-bricks as genetic building blocks which are DNA sequences that can be assembled to create complex biological systems.